首页|利伐沙班治疗高龄非瓣膜性心房颤动合并心功能不全的临床效果及安全性

利伐沙班治疗高龄非瓣膜性心房颤动合并心功能不全的临床效果及安全性

扫码查看
目的:探究利伐沙班治疗高龄非瓣膜性心房颤动合并心功能不全的临床效果及安全性.方法:选取 2021 年 7 月—2022 年 6 月在抚州市第一人民医院接受治疗的 86 例高龄非瓣膜性心房颤动合并心功能不全患者,按照随机数字表法分为对照组和观察组,每组 43 例.对照组口服华法林钠片治疗,观察组给予利伐沙班片治疗,两组均连续治疗 3 个月.比较两组临床疗效、心功能指标[左心室射血分数(LVEF)、氨基末端-B型利钠肽前体(NT-proBNP)]、凝血功能[活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)]水平、栓塞及出血发生率.结果:治疗后,观察组总有效率为 93.02%,高于对照组的 76.74%,差异有统计学意义(P<0.05).治疗后,观察组NT-proBNP低于对照组,观察组LVEF高于对照组,差异均有统计学意义(P<0.05).治疗后,观察组APTT、TT及PT均低于对照组,差异均有统计学意义(P<0.05).观察组栓塞及出血发生率为 2.33%,显著低于对照组的23.26%,差异有统计学意义(P<0.05).结论:利伐沙班治疗高龄非瓣膜性心房颤动合并心功能不全患者可获得较为理想的临床效果,有助于改善患者的心功能及凝血功能,降低栓塞及出血发生率,安全性高.
Clinical Effect and Safety of Rivaroxaban in the Treatment of Elderly Patients with Non-valvular Atrial Fibrillation Complicate with Cardiac Insufficiency
Objective:To explore the clinical effect and safety of Rivaroxaban in the treatment of elderly patients with non-valvular atrial fibrillation complicate with cardiac insufficiency.Method:A total of 86 elderly patients with non-valvular atrial fibrillation complicated with cardiac insufficiency who received treatment in First People's Hospital of Fuzhou from July 2021 to June 2022 were selected and divided into the control group and the observation group,with 43 cases in each group.The control group was treated with Warfarin Sodium Tablets,and the observation group was treated with Rivaroxaban Tablets.Both groups were treated for 3 months.The clinical efficacy,cardiac function indexes[left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptide(NT-proBNP)],coagulation function[activated partial thromboplastin time(APTT),thrombin time(TT),prothrombin time(PT)]levels,embolism and bleeding incidence were compared between the two groups.Result:After treatment,the total effective rate of the observation group was 93.02%,which was higher than 76.74%of the control group,the difference was statistically significant(P<0.05).After treatment,the NT-proBNP in the observation group was lower than that in the control group,the LVEF in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).After treatment,APTT,TT and PT in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of embolism and bleeding in the observation group was 2.33%,which was significantly lower than 23.26%in the control group,the difference was statistically significant(P<0.05).Conclusion:Rivaroxaban in the treatment of elderly patients with non-valvular atrial fibrillation complicate with cardiac insufficiency can obtain relatively ideal clinical effect,which is helpful to improve the cardiac function and coagulation function of patients,reduce the incidence of embolism and bleeding,and has high safety.

Non-valvular atrial fibrillation complicate with cardiac insufficiencyElderly patientsRivaroxabanWarfarinCardiac insufficiencyCoagulation function

曾炫

展开 >

抚州市第一人民医院心内科 江西 抚州 344000

非瓣膜性心房颤动合并心功能不全 高龄患者 利伐沙班 华法林 心功能不全 凝血功能

2024

中国医学创新
中国保健协会

中国医学创新

影响因子:1.706
ISSN:1674-4985
年,卷(期):2024.21(1)
  • 19